In our series, 83.6% of the NSCLC patients were found to be at an advanced stage needing prognostic and predictive factor assessment to select the most appropriate therapy; 96% of the adenocarcinoma samples were suitable for ALK, ROS1 and PD‐L1 assessment, whereas, mainly due to tumor necrosis and/or small amount of viable neoplastic cells, just 81% of the squamous cell carcinomas were adequate for TPS PD‐L1 assessment. This evidence concerns the gene ROS1 and adenocarcinoma.